194 related articles for article (PubMed ID: 24865624)
1. PDE inhibitors currently in early clinical trials for the treatment of asthma.
Matera MG; Page C; Cazzola M
Expert Opin Investig Drugs; 2014 Sep; 23(9):1267-75. PubMed ID: 24865624
[TBL] [Abstract][Full Text] [Related]
2. Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases.
Abbott-Banner KH; Page CP
Basic Clin Pharmacol Toxicol; 2014 May; 114(5):365-76. PubMed ID: 24517491
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
Franciosi LG; Diamant Z; Banner KH; Zuiker R; Morelli N; Kamerling IM; de Kam ML; Burggraaf J; Cohen AF; Cazzola M; Calzetta L; Singh D; Spina D; Walker MJ; Page CP
Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275
[TBL] [Abstract][Full Text] [Related]
4. Selective PDE inhibitors as novel treatments for respiratory diseases.
Page CP; Spina D
Curr Opin Pharmacol; 2012 Jun; 12(3):275-86. PubMed ID: 22497841
[TBL] [Abstract][Full Text] [Related]
5. Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease.
Cazzola M; Page C; Calzetta L; Matera MG
Pharm Pat Anal; 2018 Nov; 7(6):249-257. PubMed ID: 30657422
[TBL] [Abstract][Full Text] [Related]
6. Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD.
Cazzola M; Calzetta L; Rogliani P; Matera MG
Expert Opin Investig Drugs; 2019 Oct; 28(10):827-833. PubMed ID: 31474120
[No Abstract] [Full Text] [Related]
7. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Page CP
Int Arch Allergy Immunol; 2014; 165(3):152-64. PubMed ID: 25532037
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase inhibitors in the treatment of inflammatory diseases.
Page CP; Spina D
Handb Exp Pharmacol; 2011; (204):391-414. PubMed ID: 21695650
[TBL] [Abstract][Full Text] [Related]
10. Experimental and investigational phosphodiesterase inhibitors in development for asthma.
Ntontsi P; Detta A; Bakakos P; Loukides S; Hillas G
Expert Opin Investig Drugs; 2019 Mar; 28(3):261-266. PubMed ID: 30678501
[TBL] [Abstract][Full Text] [Related]
11. Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review.
Martin C; Burgel PR; Roche N
Int J Chron Obstruct Pulmon Dis; 2021; 16():2363-2373. PubMed ID: 34429594
[TBL] [Abstract][Full Text] [Related]
12. Tetomilast: new promise for phosphodiesterase-4 inhibitors?
Bickston SJ; Snider KR; Kappus MR
Expert Opin Investig Drugs; 2012 Dec; 21(12):1845-9. PubMed ID: 23043390
[TBL] [Abstract][Full Text] [Related]
13. Selective phosphodiesterase 4 inhibitors in the treatment of allergy and inflammation.
Smith VB; Spina D
Curr Opin Investig Drugs; 2005 Nov; 6(11):1136-41. PubMed ID: 16312135
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a novel orally active PDE-4 inhibitor effective in an ovalbumin-induced asthma murine model.
Kwak HJ; Nam JY; Song JS; No Z; Yang SD; Cheon HG
Eur J Pharmacol; 2012 Jun; 685(1-3):141-8. PubMed ID: 22554769
[TBL] [Abstract][Full Text] [Related]
15. Superiority of combined phosphodiesterase PDE3/PDE4 inhibition over PDE4 inhibition alone on glucocorticoid- and long-acting β2-adrenoceptor agonist-induced gene expression in human airway epithelial cells.
BinMahfouz H; Borthakur B; Yan D; George T; Giembycz MA; Newton R
Mol Pharmacol; 2015 Jan; 87(1):64-76. PubMed ID: 25324049
[TBL] [Abstract][Full Text] [Related]
16. Cyclic nucleotide phosphodiesterase isoenzymes and asthma--outstanding issues.
Nicholson CD
Agents Actions Suppl; 1993; 43():3-12. PubMed ID: 8396317
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase inhibitors: history of pharmacology.
Schudt C; Hatzelmann A; Beume R; Tenor H
Handb Exp Pharmacol; 2011; (204):1-46. PubMed ID: 21695634
[TBL] [Abstract][Full Text] [Related]
18. Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies.
Giembycz MA; Newton R
Handb Exp Pharmacol; 2011; (204):415-46. PubMed ID: 21695651
[TBL] [Abstract][Full Text] [Related]
19. A review of mometasone furoate / formoterol in the treatment of asthma.
Westergaard CG; Porsbjerg C; Backer V
Expert Opin Pharmacother; 2013 Feb; 14(3):339-46. PubMed ID: 23363416
[TBL] [Abstract][Full Text] [Related]
20. New Avenues for Phosphodiesterase Inhibitors in Asthma.
Matera MG; Ora J; Cavalli F; Rogliani P; Cazzola M
J Exp Pharmacol; 2021; 13():291-302. PubMed ID: 33758554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
